BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC

Backgroundand objectives: Patients with BRAF-mutated metastatic colorectal cancer have considerably poorer responses to conventional systemic treatment. The real-world effects of triplet therapy with BRAF, mitogen-activated protein kinase kinase, and epidermal growth factor receptor inhibitors in As...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Jen-Hao, Tsai, Hsiang-Lin, Chen, Yen-Cheng, Li, Ching-Chun, Huang, Ching-Wen, Chang, Tsung-Kun, Su, Wei-Chih, Chen, Po-Jung, Liu, Yu-Peng, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707783/
https://www.ncbi.nlm.nih.gov/pubmed/34946284
http://dx.doi.org/10.3390/medicina57121339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707783/
https://www.ncbi.nlm.nih.gov/pubmed/34946284
http://dx.doi.org/10.3390/medicina57121339

Ejemplares similares